A recent study showed that combined inhibition of KIF11, either with ispinesib or ARRY-520, and KIF15, with the novel inhibitor KIF15-IN-1, synergistically and efficiently killed HeLa cells, constituting a potential strategy for overcoming chemotherapeutic resistance.36 The constant development and use of novel kinesin inhibitors in preclinical and clinical studies in other cancers reinforces the potential use of kinesin inhibitors for treating MPNSTs. This evidence concerns the gene KIF11 and cancer.